TMC207/R207910 results in five times higher activity in MDR-TB

Monday, October 27th, 2008 by hinrich

Structure of TMC207/R207910

In my last post I have highlighted the results from an early bactericidal activity study that was conducted in South Africa. Dr. Andreas Diacon of the University of Stellenbosch in South Africa Sunday has disclosed yesterday initial results from a new study at the 48th International Conference on Antimicrobials and Chemotherapy (ICAAC) in Washington DC.

This study was ondertaken with 150 patients carrying multi-drug resistant Mycobacterium tuberculosis (MDR-TB). Around half a million of patients worldwide suffer from MDR-TB. Due to the severe nature of MCR-TB, a cocktail of five different antibiotics is needed. One group of MDR-TB patients received a classic cocktail plus TMC207/R207910 while an equally large group received the same cocktail plus a placebo. In this study, TMC207/R207910 is being administered for 24 weeks.

Eight weeks after start of treatment the researchers have observed a complete removal of Mycobacterium tuberculosis form the sputum of patients for nearly half of the group (47 %) that received TMC207/R207910 as part of the cocktail. This result was achieved in only 8.7 % of the patients in the second group who received the classic cocktail with a placebo.

The findings that the drug seems to be well tolerated and initially shows effects against Mycobacterium tuberculosis that is five times higher as compared to the classic cocktail are very encouraging as Mycobacterium tuberculosis causes nearly nine million new cases of active disease and 2 million deaths each year.

Current estimates are that we will need at least two more years before TMC207/R207910 is ready for the market.

Posted in Tuberculosis